These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37259074)

  • 1. A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore.
    Ong JCM; Than H; Tripathi S; Gkitzia C; Wang X
    Cost Eff Resour Alloc; 2023 May; 21(1):34. PubMed ID: 37259074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
    Liang L; Bin-Chia Wu D; Aziz MIA; Wong R; Sim D; Leong KTG; Wei YQ; Tan D; Ng K
    J Med Econ; 2018 Feb; 21(2):174-181. PubMed ID: 28959905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
    Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y
    JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain.
    Gómez-Casares MT; Hernández-Boluda JC; Jiménez-Velasco A; Martínez-López J; Ferrario MG; Gozalbo I; Gostkorzewicz J; Subirá R
    J Health Econ Outcomes Res; 2018; 5(2):162-174. PubMed ID: 35620778
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
    Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
    JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with
    Tan DS; Chan JJ; Hettle R; Ghosh W; Viswambaram A; Yu CC
    J Gynecol Oncol; 2021 Mar; 32(2):e27. PubMed ID: 33559410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Front Immunol; 2021; 12():673636. PubMed ID: 34276662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
    Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
    J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
    Pratz KW; Chai X; Xie J; Yin L; Nie X; Montez M; Iantuono E; Downs L; Ma E
    Pharmacoeconomics; 2022 Aug; 40(8):777-790. PubMed ID: 35696071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.
    Nguyen CM; Bounthavong M; Mendes MA; Christopher ML; Tran JN; Kazerooni R; Morreale AP
    Pharmacoeconomics; 2012 Jul; 30(7):575-93. PubMed ID: 22640174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
    Chin CT; Mellstrom C; Chua TS; Matchar DB
    Singapore Med J; 2013 Mar; 54(3):169-75. PubMed ID: 23546032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia.
    Sun D; Heimall JR; Greenhawt MJ; Bunin NJ; Shaker MS; Romberg N
    JAMA Pediatr; 2022 Feb; 176(2):176-184. PubMed ID: 34779842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lifetime quality of life and cost consequences of delays in endovascular treatment for acute ischaemic stroke: a cost-effectiveness analysis from a Singapore healthcare perspective.
    Ni W; Kunz WG; Goyal M; Ng YL; Tan K; De Silva DA
    BMJ Open; 2020 Sep; 10(9):e036517. PubMed ID: 32948553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of gastrointestinal tumor (GIST) of the rectum requiring abdominoperineal resection following neoadjuvant imatinib: a cost-effectiveness analysis.
    Farid M; Ong J; Chia C; Tan G; Teo M; Quek R; Teh J; Matchar D
    Clin Sarcoma Res; 2020; 10():13. PubMed ID: 32782781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.
    Le RQ; Wang X; Zhang H; Li H; Przepiorka D; Vallejo J; Leong R; Ma L; Goldberg KB; Pazdur R; Theoret MR; De Claro A
    Oncologist; 2022 Jun; 27(6):493-500. PubMed ID: 35363318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.